ReviewVeterinary and animal science2025
Therapeutic applications of IgY in common canine and feline viral diseases.
Review in Veterinary and animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin yolk (IgY) is the major antibody in birds whose immunotherapeutic potential has been investigated in canine and feline viral diseases. Management currently focuses on supportive care (often insufficient) or prevention using vaccines (slow to develop). IgY is developed against a wide range of antigens, and commercial formulations also exist. Several therapeutic trials and case reports examine IgY as main or adjunctive treatment in feline and canine viral diseases. Objectives: To map and summarize the available evidence on IgY-based immunotherapy for viral infections of dogs and cats and assess its reported benefits and shortcomings in a scoping review following the PRISMA-ScR guidelines. Eligibility criteria: Original English-language studies, focusing on the application of IgY in treating canine and feline viral diseases. Sources of evidence: Six databases (Web of Science, Scopus, ScienceDirect, Google Scholar, PubMed, ResearchGate) were searched in October 2024 using combinations of keywords related to IgY, small animals and therapy. Charting methods: Data on study design, treatment protocol/dosage/outcome and OCEBM level of evidence score were extracted. Results: In total, 14 studies met inclusion criteria, including 7 clinical trials, 3 case series and 4 case reports; ten investigated CPV-2, while four examined feline viruses (FIV/FeLV/FIP). Most were small non-randomized clinical trials. IgY was administered orally, intravenously, and intranasally. Higher doses generally produced stronger effects. Feline studies used non-specific IgY with limited therapeutical benefit. Conclusions: IgY-based immunotherapy appeared safe, accelerated recovery and reduced mortality in most studies, but current evidence in feline viral infections is limited and non-specific. Further pathogen-specific trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.